This article presents the creation and analysis of The Pan-Cancer Proteome Atlas (TPCPA), a comprehensive mass spectrometry-based landscape of proteins across 22 cancer types from nearly a thousand human samples. This extensive proteomic resource, detailed by authors Knol et al., identifies pan-cancer and cancer type-specific proteins, leading to the discovery of potential biomarkers and therapeutic targets. Key findings include the development of a multi-cancer classifier for identifying the origin of metastases and the identification of protein markers associated with colorectal cancer consensus molecular subtypes (CMS). The work, published in Cancer Cell in 2025, emphasizes the utility of high-throughput proteome profiling for understanding tumor heterogeneity and advancing clinical applications like subtype classification and target identification.

References:

• Knol J C, Lyu M, Böttger F, et al. The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets[J]. Cancer Cell, 2025.